Showing posts with label Gadolinium. Show all posts
Showing posts with label Gadolinium. Show all posts

Monday, October 22, 2007

Gadolinium Side Effects

As of April 3, 2007, the Food and Drug Administration has received another 65 cases of Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD). This confirms suspicions that contrast agents Magnevist, MultiHance, Omniscan, OptiMARK and ProHance containing gadolinium could cause this rare and potentially fatal disease as a side effect.
There are currently five FDA-approved gadolinium-based contrast agents, Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. These agents are approved for use during an MRI scan, but not for MRA. The FDA is asking health care professionals and patients to report possible cases of NSF/NFD through FDA's MedWatch program.
On May 29, 2006 the Danish Medicines Agency reported severe reactions to the common MRI contrast agent gadolinium. The agency reported 25 cases between Denmark and Austria of the extremely dangerous condition called Nephrogenic Systemic Fibrosis, sometimes called Nephrogenic Fibrosing Dermopathy. NSF or NFD is characterized by a number of diverse side effects including:

  • Tightening and swelling of the skin, usually in the extremities
  • Symmetrical skin lesions, commonly on the ankles and thighs
  • Hypertension usually precedes skin lesions
  • Reddened patches on the skin
  • Calcification of muscle, skin, tendons
  • Muscle weakness
  • Thickening of the skin around the joints, which restricts movement
  • Skin texture changes one not dissimilar to an orange peel
  • Bone pain in the hips and ribs
  • Yellow plaques near the eyes
  • Burning, itching, sharp pains in affected areas

Magnetic resonance imagery is one of the most innovative technological breakthroughs in the history of medicine. High powered magnets force the water molecules in the body into virtually perfect alignment, giving doctors an incredibly detailed and accurate picture of the inner workings of the body without having to resort to dangerous and even potentially fatal exploratory surgery. Unfortunately, even MRIs cannot depict every condition with perfect clarity, and so doctors sometimes turn to contrast marker agents, like gadolinium.
Gadolinium is a colorless, non-radioactive, water-like liquid that doctors inject into the veins of some people undergoing MRIs. Contrast markers bond with damaged or diseased tissues, giving doctors a clearer picture of potential problems. Unfortunately, gadolinium has recently been linked to a number of serious side effects, including NSF. One of the problems with diagnosing a condition as complicated as NSF is that it can take anywhere between two weeks and three months for side effects to arise, and when they do they are easily confused with other, less dangerous conditions.

Saturday, September 22, 2007

Gadolinium Attorney :: NSF Lawyer :: Nephrogenic Systemic Fibrosis Lawsuit

Gadolinium is a contrast agent that helps distinguish between normal and abnormal tissue in the body when used with magnetic resonance imaging (MRI) and/or CT scans. Gadolinium was approved for use in 1988 and has been used in millions of studies since. It is the preferred contrast agent for people with chronic kidney disease. The use of iodine-containing contrast agents is still a common cause of hospital-acquired acute renal failure and is associated with increased mortality & morbidity. On the other hand, gadolinium-based agents, like Omniscan Contrast Dye, have been reported to be safe, well tolerated, and have shown almost no nephrotoxicity in recommended doses.

Nephrogenic systemic fibrosis (NSF), described in 2000, is an emerging systemic disorder characterized by widespread tissue fibrosis. NFS was not known to the medical community before March 1997 and some medical authors suggest that the sudden occurrence of the disease in the last 8 years makes it likely that a new agent or technique of examination causes it. Currently, there is no effective treatment available for NSF.

Based on recent research, NSF occurs only in patients with advanced or in end stage kidney disease and is strongly related to the use of gadolinium dyes for MRI scans. At this time, there are no known cases of NSF in patients with normal kidney function.

In a pivotal study in 2006 conducted by Dr. T. Grobner it was noted that 5 of their 9 patients diagnosed with NSF had received a MRI involving use of Omniscan Contrast Dye, a gadolinium-based contrast agent manufactured by GE. This study was followed shortly by other studies and case reports showing a similar strong association.

Currently, little is known about NSF. However, due to recent studies, the association is so strong, that both the FDA and the company that makes gadodiamide have sent out warnings about the use of gadolinium-containing contrast in patients with advanced kidney disease.

Pending further studies, experts are recommending that gadolinium-based MRI scans be avoided in patients with advanced kidney disease until more is known about the true causal link between gadolinium and NSF.